deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02329054

Efficacy of Favipiravir Against Ebola (JIKI) (JIKI)

Efficacy of Favipiravir in Reducing Mortality in Individuals With Ebola Virus Disease in Guinea

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

Conditions Ebola Virus Disease
Interventions Favipiravir
Updated 3 times since 2024 Last updated: Nov 14, 2025 Started: Dec 31, 2014 Primary completion: May 31, 2015 Completion: Sep 30, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Ebola Virus Disease, this trial is completed. The trial is conducted by Institut National de la Santé Et de la Recherche Médicale, France and has accumulated 3 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshotCompleted~Dec 2025 – present · 5 months · monthly snapshotCompleted

Change History

3 versions recorded

  1. Dec 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

    First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Institut National de la Santé Et de la Recherche Médicale, France
Data source: Institut National de la Santé Et de la Recherche Médicale, France

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations